DekaBank Deutsche Girozentrale Grows Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

DekaBank Deutsche Girozentrale grew its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 95.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,000 shares of the biopharmaceutical company’s stock after purchasing an additional 19,000 shares during the quarter. DekaBank Deutsche Girozentrale owned approximately 0.06% of Xenon Pharmaceuticals worth $1,801,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Natixis Advisors L.P. grew its position in Xenon Pharmaceuticals by 1.3% during the second quarter. Natixis Advisors L.P. now owns 22,020 shares of the biopharmaceutical company’s stock valued at $848,000 after acquiring an additional 279 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of Xenon Pharmaceuticals by 2.2% during the 3rd quarter. Arizona State Retirement System now owns 14,478 shares of the biopharmaceutical company’s stock valued at $495,000 after purchasing an additional 313 shares during the last quarter. California State Teachers Retirement System raised its position in Xenon Pharmaceuticals by 0.8% in the 3rd quarter. California State Teachers Retirement System now owns 39,347 shares of the biopharmaceutical company’s stock worth $1,420,000 after purchasing an additional 316 shares during the period. Barclays PLC lifted its stake in Xenon Pharmaceuticals by 3.7% in the third quarter. Barclays PLC now owns 9,521 shares of the biopharmaceutical company’s stock worth $324,000 after purchasing an additional 342 shares during the last quarter. Finally, Stifel Financial Corp boosted its position in Xenon Pharmaceuticals by 3.6% during the first quarter. Stifel Financial Corp now owns 10,304 shares of the biopharmaceutical company’s stock valued at $369,000 after buying an additional 360 shares during the period. 95.45% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $62.00 price objective on shares of Xenon Pharmaceuticals in a report on Friday. JPMorgan Chase & Co. raised their target price on shares of Xenon Pharmaceuticals from $54.00 to $59.00 and gave the stock an “outperform” rating in a report on Tuesday, December 19th. Wedbush upped their price target on shares of Xenon Pharmaceuticals from $46.00 to $51.00 and gave the company an “outperform” rating in a report on Friday, March 1st. Stifel Nicolaus raised their price target on shares of Xenon Pharmaceuticals from $53.00 to $62.00 and gave the stock a “buy” rating in a report on Monday, December 18th. Finally, Citigroup initiated coverage on shares of Xenon Pharmaceuticals in a research note on Thursday, January 4th. They set a “buy” rating and a $62.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $59.44.

Xenon Pharmaceuticals Trading Down 3.9 %

Shares of NASDAQ XENE opened at $41.30 on Friday. Xenon Pharmaceuticals Inc. has a 1 year low of $27.99 and a 1 year high of $50.99. The company’s 50-day moving average is $45.50 and its 200 day moving average is $40.66.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Thursday, February 29th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.12. During the same period in the prior year, the firm earned ($0.57) EPS. The business’s revenue was up .0% on a year-over-year basis. On average, research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.04 EPS for the current fiscal year.

Insider Buying and Selling

In other Xenon Pharmaceuticals news, EVP Sherrington Robin sold 7,137 shares of the firm’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $46.28, for a total transaction of $330,300.36. Following the completion of the transaction, the executive vice president now owns 8,398 shares of the company’s stock, valued at $388,659.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Xenon Pharmaceuticals news, EVP Sherrington Robin sold 7,137 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $46.28, for a total value of $330,300.36. Following the sale, the executive vice president now owns 8,398 shares in the company, valued at $388,659.44. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Steven Gannon sold 13,000 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $46.28, for a total transaction of $601,640.00. Following the transaction, the director now owns 2,000 shares of the company’s stock, valued at $92,560. The disclosure for this sale can be found here. 5.43% of the stock is owned by insiders.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.